| Literature DB >> 26279130 |
Somaia Mohamed1, Gary R Johnson2, Julia E Vertrees3, Peter D Guarino4, Kimberly Weingart5, Ilanit Tal Young5, Jean Yoon6, Theresa C Gleason7, Katherine A Kirkwood2, Amy M Kilbourne8, Martha Gerrity9, Stephen Marder10, Kousick Biswas11, Paul Hicks12, Lori L Davis13, Peijun Chen14, AlexandraMary Kelada5, Grant D Huang15, David D Lawrence2, Mary LeGwin2, Sidney Zisook5.
Abstract
Because two-thirds of patients with Major Depressive Disorder do not achieve remission with their first antidepressant, we designed a trial of three "next-step" strategies: switching to another antidepressant (bupropion-SR) or augmenting the current antidepressant with either another antidepressant (bupropion-SR) or with an atypical antipsychotic (aripiprazole). The study will compare 12-week remission rates and, among those who have at least a partial response, relapse rates for up to 6 months of additional treatment. We review seven key efficacy/effectiveness design decisions in this mixed "efficacy-effectiveness" trial.Entities:
Keywords: Antidepressants; Antipsychotics; Major depression; Methodology; Study design; Treatment resistance
Mesh：
Substances：
Year: 2015 PMID： 26279130 DOI： 10.1016/j.psychres.2015.08.005
Source DB: PubMed Journal: Psychiatry Res ISSN： 0165-1781 Impact factor: 3.222